Validity and reliability of the Children’s Visual Function Questionnaire (CVFQ)

Birch, Eileen E.; Cheng, Christina S.; Felius, Joost

doi:10.1016/j.jaapos.2007.02.011

Cited by 85 publications

(87 citation statements)

References 15 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This approach has been used more commonly in assessing outcomes of children or those with learning disabilities. 9 In recent years, the term 'quality-of-life' (QoL) has been widely used in vision rehabilitation outcome studies. There is no single definition of quality-of-life, and the parameters assessed are often context dependent.…”

Section: Outcome Measures For Assessing the Effectiveness Of A Sermentioning

confidence: 99%

“…9,27,62,84 For example, the 25-item Cardiff Visual Ability Questionnaire for Children (CVAQC) assesses self-reported visual ability in children and young people with a visual impairment. 84 One important function of outcomes research is to assess the cost effectiveness of health and social care interventions so that policy makers can make judgments about a particular treatment/intervention.…”

Section: Outcome Measures For Assessing the Effectiveness Of A Sermentioning

confidence: 99%

“…Average 5 home visits by rehabilitation teachers (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Average number of hours nearly 7 (range 1-21).…”

Section: Engel Et Al 2000mentioning

confidence: 99%

See 2 more Smart Citations

How Effective is Low Vision Service Provision? A Systematic Review

Binns

Bunce

Dickinson

et al. 2012

Survey of Ophthalmology

204

209

View full text Add to dashboard Cite

This is the unspecified version of the paper.This version of the publication may differ from the final published version. Permanent repository link Abstract.Visual impairment is a large and growing socioeconomic problem. Good evidence on rehabilitation outcomes is required to guide service development and improve the lives of people with sight loss.Of the 478 potentially relevant articles identified, only 58 studies met our liberal inclusion criteria, and of these only 7 were randomized controlled trials. Although the literature is sufficient to confirm that rehabilitation services result in improved clinical and functional ability outcomes, the effects on mood, vision-related quality of life (QoL) and health-related QoL are less clear. There are some good data on the performance of particular types of intervention, but almost no useful data about outcomes in children, those of working age and other minority groups. There were no reports on cost effectiveness. Overall, the number of well designed and adequately reported studies is pitifully small; visual rehabilitation research needs higher quality research. We highlight study design and reporting considerations and suggest a future research agenda.

show abstract

Section: Outcome Measures For Assessing the Effectiveness Of A Sermentioning

confidence: 99%

Section: Outcome Measures For Assessing the Effectiveness Of A Sermentioning

confidence: 99%

See 1 more Smart Citation

How Effective is Low Vision Service Provision? A Systematic Review

Binns

Bunce

Dickinson

et al. 2012

Survey of Ophthalmology

204

209

View full text Add to dashboard Cite

show abstract

“…Studies using parental proxy VR-QoL-tools such as the Children's Visual Function Questionnaire found that family impact and treatment difficulty scores are worse in families of children with unilateral compared with those with bilateral cataracts, and in those treated with an aphakic contact lens compared with those treated with an intraocular lens implant 9 . Bilateral congenital/infantile cataract is associated with reduced VR-QoL scores EYE-16-281R2 December 7, 2016 5 compared to healthy controls 10 .…”

Section: Introductionmentioning

confidence: 99%

Quality of life and functional vision in children treated for cataract—a cross-sectional study

Tailor

Abou-Rayyah

Brookes

et al. 2017

Eye

View full text Add to dashboard Cite

show abstract

“…[56][57][58] Visual ability and QOL measures that assess the impact of vision loss in children have been examined in a variety of pediatric eye diseases, with most designed to evaluate children between 8 and 18 years of age. [59][60][61][62][63] Using the review process developed by the REiNS Patient-Reported Outcomes Subcommittee (see Wolters et al, this supplement), we reviewed the available pediatric questionnaires. Of these, 2 examined visual ability rather than visionspecific QOL.…”

mentioning

confidence: 99%

Functional outcome measures for NF1-associated optic pathway glioma clinical trials

et al. 2013

View full text Add to dashboard Cite

Objective: The goal of the Response Evaluation in Neurofibromatosis and Schwannomatosis Visual Outcomes Committee is to define the best functional outcome measures for future neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG) clinical trials. Methods:The committee considered the components of vision, other ophthalmologic parameters affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at consensus-based, evidence-driven recommendations for objective and measurable functional endpoints for OPG trials.Results: Visual acuity (VA) assessments using consistent quantitative testing methods are recommended as the main functional outcome measure for NF1-OPG clinical trials. Teller acuity cards are recommended for use as the primary VA endpoint, and HOTV as a secondary endpoint once subjects are old enough to complete it. The optic disc should be assessed for pallor, as this appears to be a contributory variable that may affect the interpretation of VA change over time. Given the importance of capturing patient-reported outcomes in clinical trials, evaluating visual quality of life using the Children's Visual Function Questionnaire as a secondary endpoint is also proposed. Conclusions:The use of these key functional endpoints will be essential for evaluating the efficacy of future OPG clinical trials. Neurology ® 2013;81 (Suppl 1):S15-S24 GLOSSARY CVFQ 5 Children's Visual Function Questionnaire; logMAR 5 logarithm of the minimum angle of resolution; MS 5 multiple sclerosis; NF1 5 neurofibromatosis type 1; OCT 5 optical coherence tomography; OPG 5 optic pathway glioma; PFS 5 progression-free survival; QOL 5 quality of life; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; RNFL 5 retinal nerve fiber layer; TAC 5 Teller acuity cards; VA 5 visual acuity; VEP 5 visual evoked potential; VF 5 visual field.Optic pathway gliomas (OPG) arise in 15%-20% of children with neurofibromatosis type 1 (NF1), occur preferentially in young children compared with adolescents or adults, and cause vision loss in as many as half of those affected.1 In this regard, the main objective in clinical management of these tumors is preservation of visual function. Although prognostic factors have been identified, there are currently no reliable indicators of future visual loss. This absence of prognostic signs has led clinicians to avoid initiating treatment until visual function has declined. When treatment is indicated, NF1-OPG are typically managed with a combination of carboplatin and vincristine-an approach that has not changed in 15 years. 2To date, OPG clinical trials have focused on imaging outcomes, with tumor response and/or progression-free survival used as measures of treatment success.

show abstract

Validity and reliability of the Children’s Visual Function Questionnaire (CVFQ)

Abstract: The CVFQ subscales quantified meaningful differences among pediatric patient groups who were chosen to address key research questions commonly posed in ophthalmic clinical trials.

Cited by 85 publications

References 15 publications

How Effective is Low Vision Service Provision? A Systematic Review

How Effective is Low Vision Service Provision? A Systematic Review

Quality of life and functional vision in children treated for cataract—a cross-sectional study

Functional outcome measures for NF1-associated optic pathway glioma clinical trials

Contact Info

Product

Resources

About